Followers | 0 |
Posts | 1,934 |
Boards Moderated | 0 |
Alias Born | 03/04/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LATEST UPDATE $RBII
Here is a look 👀 at our new 510 atomizer vape cartridge designed and manufactured by PAOG & High End Products featuring their exclusive C-CUP dual ceramic heating coils. 💨 #Cannophen #RBII #PAOG #C-CUP #CCUP #GetHIGHEND pic.twitter.com/B4JgunSekn
— Rising Biosciences (@RisingBioscien1) July 18, 2019
Solid progress: "Stated Mr. Hall, “I have just received the UPC symbols for both the oral capsules and vape cartridges for our CBD only variant of Cannophen ™" $RBII
$RBII new packaging for CBD only Cannophen is PERFECT for the larger mainstream market that CBD only variant can reach.
$RBII We are nearing the final stages of releasing CBD only Cannophen for distribution, Stated Mr. Hall, I have just received the UPC symbols for both the oral capsules and vape cartridges for our CBD only variant of Cannophen .
This is the same premium Cannophen that we debuted in June, with the full spectrum of CBD distillates engineered to be rapidly bioactivated by the body, only this variant is non-THC.
I am thrilled that we can now launch our CBD only variant of Cannophen, exclaimed Art Hall, CEO of Rising Biosciences.
GM $RBII
Cannophen launch is a big tipping point for $PAOG
$15 Billion anxiety treatment market, what an opportunity for $RBII
$PAOG They grow, process, and transport premium medical cannabis products for the treatment of chronic and terminal patients.
Cannophen was already debuted in June. The exciting part is that we should see the CBD only version come out soon! $RBII
$RBII will make a major impact on the opioid crisis in Midwest.
$RBII 3 fold business model does a great job making the most of this opportunity.
$RBII I like the direction of these current developments, not only pharmaceutical development but treatment management. Sounds lucrative.
$RBII nice accumulation here.
i think in the future $RBII Cannophen finding more and more distribution channels.
looks like Art will keep based with their latest development.
CBD only variant of Cannophen Capsules and Vape Cartridges is a good thing for $RBII
The market needs more awareness of Pilot Production Run means to $RBII
$RBII 510 atomizer vape cartridge is an excellent product. $RBII
We have solid developments here $RBII Big pop coming
$RBII increasing vol each day, gonna go hard once it gets unleashed
$PAOG will be the big Cannabis runner of 2019.
Some light volume coming in. $RBII
$RBII Strong out of the gate. to the yesterday news.
$RBII Market is reacting well to the news yesterday.
Looking good here $RBII
CBD only Cannophen coming soon, and that means we will be on track to really explode distribution. $PAOG
$PAOG once they launch the CBD only variant of Cannophen, they will be able to sell it online.
$PAOG holdings include RSB Management, Inc. – a team of highly experienced business management professionals focused on expanding the medical cannabis market in Michigan and other medically legal States in the USA. RSB manages a Michigan-based limited-liability corporation, High End Products LLC, which is currently in the process of applying for medical marijuana facility licensing in the state of Michigan through the Department of Licensing And Regulatory Affairs (LARA).
$PAOG plans to announce a release for the 1:1 vape cartridges, which will also feature premium THC distillate and full-spectrum CBD distillate along with organic terpenes, in the near future.
$PAOG CEO Karl Riedel announced, “We were very excited to launch Cannophen™ and Fender Benders™ at the HIGH TIMES Michigan Cannabis Cup. It was an amazing learning experience for the PAOG executive team, and we were proud to debut Cannophen™ at such a world class event. The Cannabis Cup offered us a chance to showcase the effectiveness of our products to leading industry insiders. We met with many patients, as well as provisioning centers that will enable us to expand our distribution channels. Overall, it was an amazing opportunity to hit the ground with a tangible product launch, and we are excited to shift focus to business development throughout the state Michigan.”
GM everyone
$RBII They are planning on converting it into a rehab center to fight the Opioid Crisis Big things coming.
$RBII Fighting Opiod Crisis Huge biotech company
$RBII Severely Undervalued Biotech Cannabis company that should be trading multiple pennies
$RBII I hope to hear an update on SNB health subsidiary.
$RBII Cannophen CBD only should open up a global market for $RBII, especially if they take an online distribution approach.
$RBII Anxiety disorders are the most commonly diagnosed mental health illness in the USA today, affecting more than 40 million adults. Globally, the anxiety and depression treatment market has been valued at over $15 billion. Perhaps most promising, however, are the results from recent studies indicating that CBD may be a highly effective treatment for opioid use disorder. Initial results seem to indicate that CBD could change the face of opioid addiction treatment, succeeding where other conventional therapies have had mixed results.
$RBII Growing numbers of clinical studies suggest that there is untapped potential in CBD as a treatment for a broad range of ailments from chronic anxiety to substance abuse disorder.